Oric Pharmaceuticals Falls 27% After J&J Prostate Cancer Data

Why Oric Pharmaceuticals Stock Is Falling Today

Oric Pharmaceuticals (NASDAQ: ORIC) is down 27% at $9.61 by early afternoon. Johnson & Johnson, a drugmaker developing a rival prostate cancer treatment, reported early results that raised competition concerns. A stronger rival could limit future sales of Oric’s experimental prostate cancer drug Rinzimetostat.

JNJ-6143 Prostate Cancer Trial Results

J&J’s experimental prostate cancer drug JNJ-6143 produced confirmed complete or partial responses in 75% of patients whose tumors were large enough to measure on scans. That means tumors shrank substantially or disappeared, with follow-up checks confirming the change. Phase one, an early human trial mainly testing safety and dosing, does not establish which competing drug works better.

What Oric Pharmaceuticals Inc. Does

Oric develops cancer medicines aimed at treatment resistance, when tumors stop responding to drugs. Rinzimetostat is being tested with another prostate cancer medicine in a large study intended to support a regulatory decision. The rival findings do not change results from Oric’s own trial.

Oric Pharmaceuticals Volume Rises After Rival Data

Trading reached about 4.1 million shares, about four times the usual pace for this hour. That shows unusually strong interest in the news, but cannot establish whether selling is finished.

Quick Financial Overview

Oric’s trial funding includes $264.8M in cash, cash equivalents, and short-term investments as of June 30, 2026; cash equivalents are holdings that can quickly be converted into cash. That covers about twenty-five months at its latest quarterly spending rate. Its $996.1M market capitalization, the total value of its shares, makes it a small-cap, or a smaller public company.

Oric Pharmaceuticals Quarterly Cash Use

Oric used $31.6M to run its business during the quarter and reported a net loss of $41.5M. Cash spending shows how quickly trial work uses its reserves; the reported loss also includes accounting costs.

Oric Pharmaceuticals Stock Is Near Its Monthly Low

Oric traded around the low $13s a month ago and reached the mid $9s today, near its monthly low. The decline adds to an existing slide. For scale, the last daily move this large was fifty-eight sessions ago.

Oric Pharmaceuticals Lung Cancer Trial Start

Oric expects to start a global Phase 3 trial, a large study intended to support approval, in the first half of next year. It will test its lung cancer drug Enozertinib in previously untreated patients with certain gene changes. Starting the trial would advance a separate program, without answering the prostate cancer competition question.

Conclusion

The ongoing prostate cancer trial remains the direct test: favorable results would support Rinzimetostat’s case, while disappointing findings would weaken it. No results date has been announced for that study. Oric’s cash covers the wait for its planned next steps at the reported spending rate.